Veru

What Veru does

Veru Inc. (NASDAQ: VERU) is a Miami-headquartered, late clinical-stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. Originally founded in 1993 as The Female Health Company and rebranded Veru Inc., the company operates as a publicly traded Florida corporation with 101-250 employees and a footprint spanning the United States, the United Kingdom, and Malaysia through wholly-owned legacy subsidiaries. The company has fully pivoted its strategic focus toward two clinical-stage drug candidates: enobosarm, a novel oral selective androgen receptor modulator (SARM) intended to preserve lean mass, physical function, and bone density in older patients (age 65+, BMI 35+) undergoing GLP-1 receptor agonist therapy for obesity; and sabizabulin, a novel oral broad anti-inflammatory agent targeting atherosclerotic coronary artery disease.

The underlying technology is built on small-molecule receptor pharmacology rather than biologics or platform technologies. Enobosarm is protected by composition-of-matter and method-of-use patents extending to 2046, providing a long exclusivity runway, and the FDA has clarified acceptable primary endpoints (weight loss, physical function, or bone mineral density) for registration. Sabizabulin's broad anti-inflammatory mechanism is positioned as differentiated versus standard-of-care cardiovascular therapies. The company additionally retains legacy commercial products — FC2 Female/Internal Condom (medical device), PREBOOST/Roman Swipes (consumer health), and ENTADFI (benign prostatic hyperplasia) — which historically generated approximately $16.89 million in revenue but have been de-emphasized as capital and management attention has shifted to the clinical pipeline. The lead value-creating catalyst is the Phase 2b PLATEAU trial of enobosarm plus semaglutide, which enrolled its first patient in March 2026, with interim analysis expected in Q1 2027 and topline data in Q4 2027.

Veru's business model is currently that of a pre-revenue clinical developer funded primarily by repeated post-IPO equity issuances rather than commercial product sales. The company has raised approximately $81.4 million across three public offerings in December 2023 ($33 million), October 2025 ($25 million), and December 2025 ($23.4 million), supported by a shelf Form S-3 registration filed in April 2026 to preserve capital-raising flexibility. Cash stood at $33.0 million as of December 31, 2025 and $27.6 million as of March 31, 2026 (up from $15.8 million at September 30, 2025), giving roughly one to two years of runway at current burn. Go-to-market upon any approval would rely on standard pharmaceutical distribution — wholesale distributors, retail pharmacies, and direct-to-provider channels — but the company does not yet have a commercial sales infrastructure in place. Institutional ownership is approximately 47.2% and a consensus analyst price target of $22.50 implies significant equity optionality tied to clinical readouts rather than current cash flows.

Name

Veru

Legal name

Veru Inc.

Website

https://verupharma.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

Veru Inc. is a late clinical-stage biopharmaceutical company developing enobosarm, a SARM to preserve lean mass during GLP-1 obesity therapy, and sabizabulin, a broad anti-inflammatory for atherosclerotic coronary artery disease, while commercializing legacy products including the FC2 female condom.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAE

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Biopharmaceutical development
• Cardiometabolic disease drugs
• Selective androgen receptor modulators
• Anti-inflammatory therapeutics
• Obesity treatment pharmaceuticals

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue late clinical stage biopharmaceutical company. Currently developing drugs in clinical trials with no approved products generating revenue. The company had $16.89 million in revenue as mentioned in one source (likely from existing products like FC2 female condom or other legacy products).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Veru Inc. is a late clinical-stage biopharmaceutical company developing novel oral medicines for cardiometabolic and inflammatory diseases. Its lead drug candidates are enobosarm, a selective androgen receptor modulator (SARM) intended to preserve lean mass and physical function in patients undergoing GLP-1 weight loss therapy, and sabizabulin, an oral broad anti-inflammatory agent for atherosclerotic coronary artery disease. The company also manufactures and sells legacy consumer health products including the FC2 Female/Internal Condom and PREBOOST medicated wipes.

Product overview

Veru Inc. is a late clinical stage biopharmaceutical company developing novel medicines for cardiometabolic and inflammatory diseases. The company's product portfolio consists of two main drug candidates in development: enobosarm (a SARM) for obesity treatment in combination with GLP-1 therapies, and sabizabulin (a broad anti-inflammatory) for atherosclerotic coronary artery disease. Additionally, the company manufactures and commercializes consumer health products including the FC2 Female/Internal Condom device and PREBOOST medicated wipes for premature ejaculation. The company is also developing enobosarm in combination with semaglutide (Wegovy) in the Phase 2b PLATEAU clinical trial targeting older patients with obesity.

Differentiator

Problem solved

Functional benefit

Brands

• FC2 Female Condom: Internal/female condom product for protection during sexual intercourse
• FC2 Internal Condom
• Preboost
• Roman Swipes
• ENTADFI
• enobosarm
• sabizabulin

Products and services

• Enobosarm A novel, oral, selective androgen receptor modulator (SARM) being developed to preserve lean mass, improve physical function, and maintain bone density while enhancing fat loss when combined with GLP-1 receptor agonists in patients undergoing weight loss therapy.
• Sabizabulin A novel, oral broad anti-inflammatory agent being developed to treat atherosclerotic coronary artery disease by addressing cardiometabolic inflammation.
• FC2 Female/Internal Condom A female/internal condom medical device for contraception and protection against sexually transmitted infections, manufactured, marketed, promoted, and distributed by Veru.
• PREBOOST (Roman Swipes) Medicated individual wipes marketed under the Roman Swipes brand for the prevention of premature ejaculation.
• ENTADFI A pharmaceutical product trademark held by the company, indicated for benign prostatic hyperplasia.

Quantifiable outcome

• Phase 2b QUALITY study showed enobosarm preserved lean mass while augmenting fat loss during active weight reduction therapy
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Structure Therapeutics: Clinical-stage company developing oral GLP-1 agonists (GSBR-1290) for obesity and diabetes. Comparable in obesity drug development focus and stage, with a complementary rather than directly competitive mechanism to enobosarm's muscle-preservation angle.
• Soleno Therapeutics: Late-stage biopharma developing DCCR (extended-release diazoxide) for Prader-Willi syndrome, a rare obesity disorder. Comparable small-cap clinical biopharma in obesity-adjacent metabolic indications.

Direct peers

• Axsome Therapeutics: Late-stage CNS-focused biopharma that has successfully launched novel therapeutics (Auvelity, Sunosi). Comparable small/mid-cap clinical biopharma with similar transition from clinical development to commercialization.
• Viking Therapeutics: Late-stage clinical biopharma developing VK2735, an injectable and oral GLP-1/GIP agonist for obesity. Most directly comparable to Veru as another small-cap obesity-focused drug developer with similar pipeline stage and market positioning.
• Madrigal Pharmaceuticals: Cardiometabolic specialty pharma that developed and commercialized resmetirom (Rezdiffra) for MASH/NASH. Comparable late-stage cardiometabolic developer with similar market cap profile and clinical-to-commercial transition.
• Esperion Therapeutics: Cardiometabolic specialty pharma with commercial cardiovascular products (Nexletol, Nexlizet) for LDL lowering. Comparable cardiometabolic focus with similar size and late-stage-to-commercial positioning.
• Crinetics Pharmaceuticals: Late clinical-stage endocrinology-focused biopharma developing paltusotine for acromegaly and an oral obesity candidate. Comparable small-cap clinical biopharma pursuing endocrine/metabolic indications with similar size and stage.

Broad incumbents

• Novo Nordisk: Market leader for GLP-1 therapy with Wegovy (semaglutide) and Ozempic, the drug being combined with enobosarm in the PLATEAU trial. Defines the addressable market opportunity and competitive backdrop.
• Innoviva: Specialty pharma holding company with royalty/development interests in infectious disease and critical care. Comparable small-cap specialty pharma with diversified therapeutic focus and similar market cap profile.
• Eli Lilly: Market leader for GLP-1 obesity therapy with Zepbound (tirzepatide). Relevant incumbent defining the obesity treatment paradigm that enobosarm is designed to complement with muscle preservation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/veru-inc
• Xx.com/Veru_Pharma
• Facebookfacebook.com/VeruPharmaInc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Veru